Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II imatinib mesylate in refractory thymic epithelial tumours or Langerhans cell histiocytosis
2007-006119-22Phase 2Active
- Sponsor
- University of Naples Federico II
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in thymic malignancies (TET), Langerhans cell histiocytosis (LCH) and thymic epithelial tumors (TET), sponsored by University of Naples Federico II. Primary endpoint: Efficacy (activity) of imatinib mesylate. Started Oct 2008; status: active.
02
Drugs
03
Conditions
thymic malignancies (TET)Langerhans cell histiocytosis (LCH)thymic epithelial tumors (TET)
Beyond the preview
Go deeper on 2007-006119-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006119-22.